Ariad Pharmaceuticals Inc. was denied a breakthrough designation from FDA for its ALK/EGFR inhibitor AP26113 in non-small cell lung cancer, the company admitted during its second quarter earnings call, though the firm may try again.
The request was denied “because of the relatively short follow-up of many of the ALK-positive patients treated with ‘113 to date and the small numbers,” Timothy Clackson, Ariad’s chief scientific...